1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61926
Full metadata record
DC FieldValueLanguage
dc.creatorAna Delia Pinzón Garcíapt_BR
dc.creatorRubén Dario Sinisterra Millánpt_BR
dc.creatorMaría Esperanza Cortés Segurapt_BR
dc.creatorFredy Mesapt_BR
dc.creatorSandra Ramírez-Clavijopt_BR
dc.date.accessioned2023-12-12T18:45:53Z-
dc.date.available2023-12-12T18:45:53Z-
dc.date.issued2021-
dc.citation.volume9pt_BR
dc.citation.spagee12124pt_BR
dc.identifier.doihttps://doi.org/10.7717/peerj.12124pt_BR
dc.identifier.issn2167-8359pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61926-
dc.description.resumoBreast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.pt_BR
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORApt_BR
dc.publisher.departmentICX - DEPARTAMENTO DE QUÍMICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofPeerJpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectTamoxifen citratept_BR
dc.subjectNanofiberspt_BR
dc.subjectPolycaprolactonept_BR
dc.subjectBreast Cancerpt_BR
dc.subject.otherBioquímicapt_BR
dc.subject.otherBioengenhariapt_BR
dc.subject.otherBiotecnologia farmacêuticapt_BR
dc.subject.otherMamas - Câncerpt_BR
dc.subject.otherCâncer - Tratamentopt_BR
dc.subject.otherReceptores hormonaispt_BR
dc.subject.otherTecnologia de liberação controladapt_BR
dc.titlePolycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cellspt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://peerj.com/articles/12124/pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-8876-4907pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-7656-1849pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0560-8491pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells.pdf1.04 MBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.